EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische Studie

Regression effect of renin–angiotensin–aldosterone system inhibitors on Kawasaki disease patients with coronary artery aneurysm: a prospective, observational study

Eisuke Suganuma, Masaru Miura, Yutaro Koyama, Tohru Kobayashi, Tetsuji Kaneko, Tatsunori Hokosaki, Fujito Numano, Kenji Furuno, Junko Shiono, Shigeto Fuse, Ryuji Fukazawa, Yoshihide Mitani

European Journal of Pediatrics · 2024

DOI: 10.1007/s00431-024-05765-3 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift European Journal of Pediatrics, 2024. Verfasst von Eisuke Suganuma und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases and Immunology and Allergy, Saitama Children's Medical Center, Saitama, Japan. Hauptthemen laut MEDLINE: Mucocutaneous Lymph Node Syndrome, Angiotensin-Converting Enzyme Inhibitors, Coronary Aneurysm. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: This study is to investigate whether angiotensin type 1 receptor blockers (ARBs) or angiotensin-converting enzyme inhibitors (ACEis) can regress coronary artery aneurysm (CAA) in patients with Kawasaki disease (KD). METHODS: This multicenter, prospective, observational study was conducted at 53 institutions throughout Japan. We enrolled patients who were diagnosed with KD after January 2015 and had a medium or large CAA (maximum luminal diameter ≥ 4 mm or z score ≥ + 5) 30 days or later after KD onset. RESULTS: Of the 209 patients, 47 (22%) were taking ARBs/ ACEis. Compared with those in the non-ARB/ACEi group, the baseline CAA diameter was significantly greater (6.7 mm vs. 5.5 mm, p < 0.01), and bilateral CAA (70% vs. 59%, p = 0.01) and giant CAA (32% vs. 20%, p = 0.08) were more frequently observed in the ARB/ACEi group. Although the overall regression rates did not differ between the groups (67% vs. 65%), the regression rates of giant CAA were approximately 1.6 times greater in the ARB/ACEi group than in the non-ARB/ACEi group (36% vs. 23%). Multivariate Cox regression analysis after adjustment for other clinical variables suggested that ARBs/ACEis may be a factor in CAA regression (hazard ratio [HR]: 1.5, 95% confidence interval [CI]: 0.91-2.46). CONCLUSIONS: Although ARBs/ ACEis were used more frequently in patients with severe CAA, these patients had similar CAA regression rates to patients not taking ARBs/ACEis. ARBs/ACEis may be beneficial agents aimed at inducing CAA regression in KD patients. WHAT IS KNOWN: • Large CAAs are less likely to regress and are always at risk of life-threatening cardiac events. • Moderate CAA, age less than 1 year, and female sex have been reported to be factors that promote the regression of CAA. WHAT IS NEW: • Although ARBs/ACEis were used more frequently in patients with severe CAA, these patients had a similar rate of CAA regression to patients who did not take ARBs/ACEis. • The regression rates of giant CAA were approximately 1.6 times greater in the ARB/ACEi group than in the non-ARB/ACEi group.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mucocutaneous Lymph Node SyndromeAngiotensin-Converting Enzyme InhibitorsCoronary AneurysmHumansMaleFemaleProspective StudiesChild, PreschoolInfantJapanTreatment OutcomeChildRenin-Angiotensin SystemAngiotensin Receptor AntagonistsAngiotensin II Type 1 Receptor Blockers

Stichwörter der Autor:innen

Angiotensin IICoronary artery aneurysmKawasaki diseaseRegression

Substanzen

Angiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsAngiotensin II Type 1 Receptor Blockers

Autor:innen und Institutionen

  • Division of Infectious Diseases and Immunology and Allergy, Saitama Children's Medical Center, Saitama, Japan.
  • Department of Cardiology, Tokyo Metropolitan Children's Medical Center, 2-18-29 Musashidai, Fuchu, Tokyo, 183-8561, Japan. masaru10miura@gmail.com.
  • Department of Cardiology, Tokyo Metropolitan Children's Medical Center, 2-18-29 Musashidai, Fuchu, Tokyo, 183-8561, Japan.
  • Department of Data Science, Clinical Research Center, National Center for Child Health and Development, Tokyo, Japan.
  • Clinical Research Support Center, Tokyo Metropolitan Children's Medical Center, 2-18-29 Musashidai, Fuchu, Tokyo, 183-8561, Japan.
  • Department of Pediatric Cardiology, Yokohama City University Hospital, Kanagawa, Japan.

Zitieren

APA

Suganuma, E., Miura, M., Koyama, Y., Kobayashi, T., Kaneko, T., Hokosaki, T., Numano, F., Furuno, K., Shiono, J., Fuse, S., Fukazawa, R., & Mitani, Y. (2024). Regression effect of renin–angiotensin–aldosterone system inhibitors on Kawasaki disease patients with coronary artery aneurysm: a prospective, observational study. European Journal of Pediatrics. https://doi.org/10.1007/s00431-024-05765-3

Vancouver

Suganuma E, Miura M, Koyama Y, Kobayashi T, Kaneko T, Hokosaki T, et al. Regression effect of renin–angiotensin–aldosterone system inhibitors on Kawasaki disease patients with coronary artery aneurysm: a prospective, observational study. European Journal of Pediatrics. 2024. doi:10.1007/s00431-024-05765-3

BibTeX
@article{Suganuma2024,
  author = {Suganuma, Eisuke and Miura, Masaru and Koyama, Yutaro and Kobayashi, Tohru and Kaneko, Tetsuji and Hokosaki, Tatsunori and Numano, Fujito and Furuno, Kenji and Shiono, Junko and Fuse, Shigeto and Fukazawa, Ryuji and Mitani, Yoshihide},
  title = {Regression effect of renin–angiotensin–aldosterone system inhibitors on Kawasaki disease patients with coronary artery aneurysm: a prospective, observational study},
  journal = {European Journal of Pediatrics},
  year = {2024},
  doi = {10.1007/s00431-024-05765-3}
}
Kostenlos starten →